Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.

Radamaker L, Lin YH, Annamalai K, Huhn S, Hegenbart U, Schönland SO, Fritz G, Schmidt M, Fändrich M.

Nat Commun. 2019 Mar 20;10(1):1103. doi: 10.1038/s41467-019-09032-0.

2.

AL amyloidosis with a localized B cell neoplasia.

Stuhlmann-Laeisz C, Schönland SO, Hegenbart U, Oschlies I, Baumgart JV, Krüger S, Röcken C.

Virchows Arch. 2019 Mar;474(3):353-363. doi: 10.1007/s00428-019-02527-7. Epub 2019 Jan 24.

PMID:
30680453
3.

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.

Dittrich T, Benner A, Kimmich C, Siepen FAD, Veelken K, Kristen AV, Bochtler T, Katus HA, Müller-Tidow C, Hegenbart U, Schönland SO.

Haematologica. 2019 Jul;104(7):1451-1459. doi: 10.3324/haematol.2018.205336. Epub 2019 Jan 17.

4.

Systemic immunoglobulin light chain amyloidosis.

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA.

Nat Rev Dis Primers. 2018 Oct 25;4(1):38. doi: 10.1038/s41572-018-0034-3. Review.

PMID:
30361521
5.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO.

Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.

6.

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.

Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e493-e499. doi: 10.1016/j.clml.2018.07.292. Epub 2018 Jul 25.

7.

MR neurography biomarkers to characterize peripheral neuropathy in AL amyloidosis.

Kollmer J, Weiler M, Purrucker J, Heiland S, Schönland SO, Hund E, Kimmich C, Hayes JM, Hilgenfeld T, Pham M, Bendszus M, Hegenbart U.

Neurology. 2018 Aug 14;91(7):e625-e634. doi: 10.1212/WNL.0000000000006002. Epub 2018 Jul 20.

PMID:
30030328
8.

Obesity is a significant susceptibility factor for idiopathic AA amyloidosis.

Blank N, Hegenbart U, Dietrich S, Brune M, Beimler J, Röcken C, Müller-Tidow C, Lorenz HM, Schönland SO.

Amyloid. 2018 Mar;25(1):37-45. doi: 10.1080/13506129.2018.1429391. Epub 2018 Jan 24.

PMID:
29364741
9.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

10.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2018 Jan 9;2(1):1-9. doi: 10.1182/bloodadvances.2017013334.

11.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.

Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N.

Haematologica. 2018 Mar;103(3):514-521. doi: 10.3324/haematol.2017.181339. Epub 2017 Dec 7.

12.

Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era.

Kristen AV, Kreusser MM, Blum P, Schönland SO, Frankenstein L, Dösch AO, Knop B, Helmschrott M, Schmack B, Ruhparwar A, Hegenbart U, Katus HA, Raake PWJ.

J Heart Lung Transplant. 2018 May;37(5):611-618. doi: 10.1016/j.healun.2017.11.015. Epub 2017 Nov 15.

PMID:
29217108
13.

First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival.

Pika T, Hegenbart U, Flodrova P, Maier B, Kimmich C, Schönland SO.

Blood. 2018 Jan 18;131(3):368-371. doi: 10.1182/blood-2017-09-806463. Epub 2017 Nov 27. No abstract available.

14.

Diagnostic work up of an adult female patient with systemic AA amyloidosis revealing the cause of infantile mental retardation.

Veelken K, Schönland SO, Gdynia G, Weber T, Blank N, Hegenbart U.

Amyloid. 2018 Mar;25(1):68-69. doi: 10.1080/13506129.2017.1405803. Epub 2017 Nov 23. No abstract available.

PMID:
29166802
15.

Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Meziane I, Huhn S, Filho MIDS, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K.

Haematologica. 2017 Oct;102(10):e411-e414. doi: 10.3324/haematol.2017.171108. Epub 2017 Jul 4. No abstract available.

16.

Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools.

Kollmer J, Sahm F, Hegenbart U, Purrucker JC, Kimmich C, Schönland SO, Hund E, Heiland S, Hayes JM, Kristen AV, Röcken C, Pham M, Bendszus M, Weiler M.

Neurology. 2017 Aug 1;89(5):475-484. doi: 10.1212/WNL.0000000000004178. Epub 2017 Jul 5.

PMID:
28679600
17.

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).

Schetelig J, de Wreede LC, Andersen NS, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhäuser M, Iacobelli S, Putter H, Schönland SO, Kröger N; CLL subcommittee, Chronic Malignancies Working Party.

Br J Haematol. 2017 Aug;178(4):521-533. doi: 10.1111/bjh.14791. Epub 2017 Jun 7.

PMID:
28589551
18.

AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, Ho AD, Hegenbart U, Schönland SO.

Blood. 2017 Aug 3;130(5):632-642. doi: 10.1182/blood-2017-02-767475. Epub 2017 May 26.

19.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

20.

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.

Haematologica. 2017 Aug;102(8):1424-1431. doi: 10.3324/haematol.2016.163246. Epub 2017 May 18.

21.

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.

Granzow M, Hegenbart U, Hinderhofer K, Hose D, Seckinger A, Bochtler T, Hemminki K, Goldschmidt H, Schönland SO, Jauch A.

Haematologica. 2017 Jul;102(7):1281-1290. doi: 10.3324/haematol.2016.160721. Epub 2017 Mar 24.

22.

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.

Schetelig J, de Wreede LC, van Gelder M, Andersen NS, Moreno C, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Henseler A, van Biezen A, Bornhäuser M, Schönland SO, Kröger N.

Bone Marrow Transplant. 2017 Apr;52(4):552-560. doi: 10.1038/bmt.2016.329. Epub 2017 Jan 23.

PMID:
28112746
23.

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

da Silva Filho MI, Försti A, Weinhold N, Meziane I, Campo C, Huhn S, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Morgan GJ, Houlston R, Goldschmidt H, Jauch A, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Hemminki K.

Leukemia. 2017 Aug;31(8):1735-1742. doi: 10.1038/leu.2016.387. Epub 2016 Dec 27.

PMID:
28025584
24.

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO.

Blood. 2016 Jul 28;128(4):594-602. doi: 10.1182/blood-2015-10-676361. Epub 2016 Jun 2.

25.

Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.

Lisenko K, Schönland SO, Jauch A, Andrulis M, Röcken C, Ho AD, Goldschmidt H, Hegenbart U, Hundemer M.

Cancer Med. 2016 Jul;5(7):1464-72. doi: 10.1002/cam4.725. Epub 2016 Apr 25.

26.

Reply to R. Warsame et al.

Bochtler T, Hegenbart U, Kunz C, Benner A, Schönland SO.

J Clin Oncol. 2015 Nov 20;33(33):3976-7. doi: 10.1200/JCO.2015.63.2141. Epub 2015 Aug 31. No abstract available.

PMID:
26324370
27.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO.

J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.

PMID:
25779559
28.

In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.

Kollmer J, Hund E, Hornung B, Hegenbart U, Schönland SO, Kimmich C, Kristen AV, Purrucker J, Röcken C, Heiland S, Bendszus M, Pham M.

Brain. 2015 Mar;138(Pt 3):549-62. doi: 10.1093/brain/awu344. Epub 2014 Dec 18.

29.

Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis.

Riffel JH, Mereles D, Emami M, Korosoglou G, Kristen AV, Aurich M, Voss A, Schonland SO, Hegenbart U, Hardt SE, Katus HA, Buss SJ.

Amyloid. 2015 Mar;22(1):45-53. doi: 10.3109/13506129.2014.992515. Epub 2014 Dec 10.

PMID:
25492308
30.

Risk factors for AA amyloidosis in Germany.

Blank N, Hegenbart U, Lohse P, Beimler J, Röcken C, Ho AD, Lorenz HM, Schönland SO.

Amyloid. 2015 Mar;22(1):1-7. doi: 10.3109/13506129.2014.980942. Epub 2014 Nov 7.

PMID:
25376380
31.

Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis.

Kristen AV, Biener M, Hegenbart U, Hardt S, Schnabel PA, Röcken C, Schonland SO, Katus HA, Giannitsis E.

Int J Cardiol. 2014 Oct 20;176(3):1113-5. doi: 10.1016/j.ijcard.2014.07.106. Epub 2014 Aug 1. No abstract available.

PMID:
25115253
32.

Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.

Kristen AV, Rosenberg M, Lindenmaier D, Merkle C, Steen H, Andre F, Schönland SO, Schnabel PA, Schuster T, Röcken C, Giannitsis E, Katus HA, Frey N.

Amyloid. 2014 Sep;21(3):202-10. doi: 10.3109/13506129.2014.940457. Epub 2014 Jul 9.

PMID:
25007036
33.

Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma.

Weinhold N, Försti A, da Silva Filho MI, Nickel J, Campo C, Hoffmann P, Nöthen MM, Hose D, Goldschmidt H, Jauch A, Langer C, Hegenbart U, Schönland SO, Hemminki K.

Leukemia. 2014 Nov;28(11):2254-6. doi: 10.1038/leu.2014.208. Epub 2014 Jul 3. No abstract available.

PMID:
24990613
34.

Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.

Bochtler T, Hegenbart U, Kunz C, Benner A, Seckinger A, Dietrich S, Granzow M, Neben K, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO.

Amyloid. 2014 Mar;21(1):9-17. doi: 10.3109/13506129.2013.854766. Epub 2014 Jan 23.

PMID:
24455967
35.

[Chronic inflammation and AA amyloidosis].

Blank N, Schönland SO.

Dtsch Med Wochenschr. 2013 Sep;138(37):1835-8. doi: 10.1055/s-0033-1349428. Epub 2013 Sep 4. Review. German.

PMID:
24006165
36.

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G.

Blood. 2013 Apr 25;121(17):3420-7. doi: 10.1182/blood-2012-12-473066. Epub 2013 Mar 11.

37.

Familial Mediterranean fever in Germany: clinical presentation and amyloidosis risk.

Ebrahimi-Fakhari D, Schönland SO, Hegenbart U, Lohse P, Beimler J, Wahlster L, Ho AD, Lorenz HM, Blank N.

Scand J Rheumatol. 2013;42(1):52-8. doi: 10.3109/03009742.2012.714796. Epub 2012 Nov 8.

PMID:
23137073
38.

Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers.

Buss SJ, Emami M, Mereles D, Korosoglou G, Kristen AV, Voss A, Schellberg D, Zugck C, Galuschky C, Giannitsis E, Hegenbart U, Ho AD, Katus HA, Schonland SO, Hardt SE.

J Am Coll Cardiol. 2012 Sep 18;60(12):1067-76. doi: 10.1016/j.jacc.2012.04.043. Epub 2012 Aug 8.

39.

CD4+CD25highCD127low regulatory T cells in peripheral blood are not an independent factor for chronic graft-versus-host disease after allogeneic stem cell transplantation.

Perz JB, Gürel S, Schonland SO, Hegenbart U, Ho AD, Dreger P.

ScientificWorldJournal. 2012;2012:606839. doi: 10.1100/2012/606839. Epub 2012 May 1.

40.

Rapid assessment of longitudinal systolic left ventricular function using speckle tracking of the mitral annulus.

Buss SJ, Mereles D, Emami M, Korosoglou G, Riffel JH, Bertel D, Schonland SO, Hegenbart U, Katus HA, Hardt SE.

Clin Res Cardiol. 2012 Apr;101(4):273-80. doi: 10.1007/s00392-011-0389-x. Epub 2011 Dec 4.

PMID:
22139127
41.

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.

Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, Lohse P, Röcken C.

Blood. 2012 Jan 12;119(2):488-93. doi: 10.1182/blood-2011-06-358507. Epub 2011 Nov 21.

42.

Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.

Schönland SO, Dreger P, de Witte T, Hegenbart U.

Bone Marrow Transplant. 2012 Jul;47(7):895-905. doi: 10.1038/bmt.2011.152. Epub 2011 Jul 25. Review.

PMID:
21785469
43.

Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis.

Kristen AV, Haufe S, Schonland SO, Hegenbart U, Schnabel PA, Röcken C, Hardt S, Lohse P, Ho AD, Haberkorn U, Dengler TJ, Altland K, Katus HA.

Int J Cardiol. 2013 Apr 5;164(2):179-84. doi: 10.1016/j.ijcard.2011.06.123. Epub 2011 Jul 20.

PMID:
21764155
44.

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14).

Bochtler T, Hegenbart U, Heiss C, Benner A, Moos M, Seckinger A, Pschowski-Zuck S, Kirn D, Neben K, Bartram CR, Ho AD, Goldschmidt H, Hose D, Jauch A, Schonland SO.

Blood. 2011 Apr 7;117(14):3809-15. doi: 10.1182/blood-2010-02-268987. Epub 2011 Feb 10.

45.

Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay.

Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, Merkle C, Hardt S, Schnabel PA, Röcken C, Schonland SO, Ho AD, Dengler TJ, Katus HA.

Blood. 2010 Oct 7;116(14):2455-61. doi: 10.1182/blood-2010-02-267708. Epub 2010 Jun 25.

46.

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.

Dietrich S, Schönland SO, Benner A, Bochtler T, Kristen AV, Beimler J, Hund E, Zorn M, Goldschmidt H, Ho AD, Hegenbart U.

Blood. 2010 Jul 29;116(4):522-8. doi: 10.1182/blood-2009-11-253237. Epub 2010 Apr 7.

47.

Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis.

Kristen AV, Sack FU, Schonland SO, Hegenbart U, Helmke BM, Koch A, Schnabel PA, Röcken C, Hardt S, Remppis A, Goldschmidt H, Karck M, Ho AD, Katus HA, Dengler TJ.

Eur J Heart Fail. 2009 Oct;11(10):1014-20. doi: 10.1093/eurjhf/hfp121.

48.

Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia.

Kirwan M, Vulliamy T, Marrone A, Walne AJ, Beswick R, Hillmen P, Kelly R, Stewart A, Bowen D, Schonland SO, Whittle AM, McVerry A, Gilleece M, Dokal I.

Hum Mutat. 2009 Nov;30(11):1567-73. doi: 10.1002/humu.21115.

PMID:
19760749
49.

[Systemic light chain amyloidosis - molecular basis and clinical perspectives].

Schönland SO, Moos M, Bochtler T, Ho AD, Hegenbart U.

Dtsch Med Wochenschr. 2009 Sep;134(39):1949-52. doi: 10.1055/s-0029-1237538. Epub 2009 Sep 16. Review. German. No abstract available.

PMID:
19760558
50.

[Risk stratification and treatment of cardiac amyloidoses].

Kristen AV, Schönland SO, Remppis A, Hegenbart U, Schnabel PA, Katus HA, Dengler TJ.

Pathologe. 2009 May;30(3):212-8. doi: 10.1007/s00292-009-1134-3. Review. German.

PMID:
19357849

Supplemental Content

Loading ...
Support Center